Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine
Sponsor: Glaxo Wellcome
Listed as NCT00000635, this NA trial focuses on HIV Infections and Herpes Simplex and remains completed. Sponsored by Glaxo Wellcome, it has been updated 7 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Dec 2021 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Dec 2021 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Glaxo Wellcome
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Aurora, United States
- • Baltimore, United States
- • Chicago, United States
- • New York, United States
- • San Francisco, United States
- • St Louis, United States